Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Summary: Retatrutide, an investigational GLP-1/GIP/glucagon triple agonist, most commonly causes gastrointestinal side effects, and no direct human fertility data currently exist, though indirect reproductive benefits via weight loss are plausible
Some metabolically sensitive imaging modalities can be used for clinical diagnosis, facilitating early detection and treatment of diseases
Maintaining weight loss requires a long-term commitment to healthy habits and may involve ongoing support from healthcare providers or weight loss programs
Those who continued GLP-1 treatment for two or two-and-a-half years before discontinuing for the remainder of the study also gained significant risk reduction (7% and 15%, respectively)
US$ 22.77
US$ 22.60
US$ 23.33
US$ 22.75
US$ 22.63
